Zhong Ji Longevity Science Group (0767) Fair Value & Analysis

Healthcare · HK · Market cap HK$312M

Below-average quality, and screening another 43% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (HK$0.2550). The favourable scenario is already priced in.
• Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (HK$0.1360 to HK$0.2550) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$0.1080 – HK$9.50 · fair‑value band HK$0.1360 – HK$0.2550 · the HK$0.3600 price screens above the HK$0.2040 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Zhong Ji Longevity Science Group (0767) currently trades at HK$0.3600, while our model-based Fair Value estimate is HK$0.2040, implying the stock looks roughly 43.3% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Zhong Ji Longevity Science Group generated revenue of HK$126M at a net margin of -13.3%. Revenue declined 37.8% year over year. It earns a return on equity of -4.0%. The balance sheet holds a net cash position of HK$18.7M. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$0.1360 (bear case) to HK$0.2550 (bull case); at HK$0.3600, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 50% below its 52-week high and 13% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -50% fair-value upside, at -43%, 0767 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Zhong Ji Longevity Science Group Limited, an investment holding company, engages in the money lending business in Hong Kong and Mainland China. It operates through Longevity Science Business; Money Lending and Financial Advisory Business; Securities and Other Investments; and Property Investment segments.

Full company description

Zhong Ji Longevity Science Group Limited, an investment holding company, engages in the money lending business in Hong Kong and Mainland China. It operates through Longevity Science Business; Money Lending and Financial Advisory Business; Securities and Other Investments; and Property Investment segments. The company is involved in the provision of diagnostic consultation, health and medical testing and checking, and distribution of healthcare cancer prevention and immunity healthcare supplements, as well as sales and distribution of longevity wine. It also engages in the holding of equity investments; investment in short and long-term financial assets; provision of loan financing and management services; and provision of financial and investment consulting, as well as financial advisory and management services; and investment in properties. In addition, the company offers health consulting services, and trades in medical products. Zhong Ji Longevity Science Group Limited was incorporated in 1994 and is based in Kowloon Bay, Hong Kong.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Zhong Ji Longevity Science Group reported revenue of HK$165M in FY2025 versus HK$63.0M in FY2021, a compound +27.3%/yr. Reported net income was −HK$16.8M in FY2025.

0767 screens 43% overvalued. Compare with Thermo Fisher Scientific Inc →

Peer Group

Diagnostics & Research · 135 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Diagnostics & Research median · lower = cheaper

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.